Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ATRA and Bryostatin 1 in Refractory AML or MDS
NCT00136461Phase 2Completed
- Sponsor
- Dana-Farber Cancer Institute
- Start
- May 1997
- Primary completion
- Aug 2000
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of bryostatin-1 in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) (2 arms), sponsored by Dana-Farber Cancer Institute. Primary endpoint: Therapeutic effect (Response) at Day 50. Started May 1997; status: completed.
02
Drugs
bryostatin-1
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT00136461.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00136461.